The type III secretion system as a source of novel antibacterial drug targets

Current Drug Targets

Volumn 13, Issue 3, 2012, Pages 338-351

  Kline, Toni ^a   Felise, Heather B ^a   Sanowar, Sarah ^a   Miller, Samuel I ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Antibiotic drug discovery; Gram negative bacteria; High throughput screening; Type III secretion; Virulence

Indexed keywords

2 ARYLSULFONYLAMINO BENZANILIDE; 5 ARYL 2 IMINOTHIAZOLIDINONE; ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; BACTERIAL PROTEIN; BENZAMIDE DERIVATIVE; CALCIUM ION; CAMINOSIDE; CAMINOSIDE A; CAMINOSIDE B; CAMINOSIDE C; CAMINOSIDE D; CHELERYTHRINE; GUADINOMINE DERIVATIVE; HYDRAZONE DERIVATIVE; INP 0010; INP 0031; INP 007; INP 0400; INP 0401; INP 0403; INP 0404; MBX 1641; NATURAL PRODUCT; OUTER MEMBRANE PROTEIN; PHOSPHOLIPASE; PHOSPHOLIPASE YPLA; THIAZOLIDINE DERIVATIVE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANCOMYCIN;

AMINO ACID SEQUENCE; ANTIBACTERIAL ACTIVITY; ARTICLE; BACTERIAL GROWTH; BACTERIAL OUTER MEMBRANE; BACTERIAL STRAIN; BACTERIAL VIRULENCE; CALCIUM DEPLETION; CHEMICAL MODIFICATION; COMPLEX FORMATION; CONSERVATION BIOLOGY; CYTOLYSIS; CYTOTOXICITY; DRUG DESIGN; DRUG INHIBITION; DRUG MECHANISM; DRUG POTENCY; DRUG SYNTHESIS; DRUG TARGETING; GENE EXPRESSION; GRAM NEGATIVE BACTERIUM; HIGH THROUGHPUT SCREENING; HUMAN; IC 50; IN VITRO STUDY; MOLECULAR BIOLOGY; NONHUMAN; PROTEIN PROCESSING; PSEUDOMONAS AERUGINOSA; QUANTITATIVE STRUCTURE ACTIVITY RELATION; STEREOCHEMISTRY; TYPE III SECRETION SYSTEM; VANCOMYCIN RESISTANT ENTEROCOCCUS;

ANIMALS; ANTI-BACTERIAL AGENTS; BACTERIAL PROTEINS; DRUG DELIVERY SYSTEMS; ESCHERICHIA COLI PROTEINS; HUMANS;

EID: 84863413409     PISSN: 13894501     EISSN: 18735592     Source Type: Journal    
DOI: 10.2174/138945012799424642     Document Type: Article

References (100)

1. Piddock LJ, Garvey MI, Rahman MM, Gibbons S. Natural and synthetic compounds such as trimethoprim behave as inhibitors of efflux in Gram-negative bacteria. J Antimicrob Chemother 2010; 65(6): 1215-1223.
2. Kline T, Trent MS, Stead CM, et al. Synthesis of and evaluation of lipid A modification by 4-substituted 4-deoxy arabinose analogs as potential inhibitors of bacterial polymyxin resistance. Bioorg Med Chem Lett 2008; 18(4): 1507-1510.
3. Bunders CA, Richards JJ, Melander C. Identification of aryl 2-aminoimidazoles as biofilm inhibitors in Gram-negative bacteria. Bioorg Med Chem Lett 2010; 20: 3797-3800.
4. Baron C. Anti-virulence drugs to target bacterial secretion systems. Curr Opin Microbiol 2010; 13(1): 100-105.
5. Marra A. Targeting virulence for antibacterial chemotherapy: identifying and characterising virulence factors for lead discovery. Drugs R D 2006; 7(1): 1-16.
6. Rasko DA, Sperandio V. Anti-virulence strategies to combat bacteria-mediated disease. Nat Rev Drug Discov 2010; 9(2): 117-128.
7. Escaich S. Anti-virulence as a new antibacterial approach for chemotherapy. Curr Opin Chem Biol 2008; 12(4): 400-408.
8. Coombes BK. Type III secretion systems in symbiotic adaptation of pathogenic and non-pathogenic bacteria. Trends Microbiol 2009; 17(3): 89-94.
9. Rasko DA, Sperandio V. Anti-virulence strategies to combat bacteria-mediated disease. Nat Rev Drug Discov; 9(2): 117-128.
10. Armstrong GD, Rowe PC, Goodyer P, et al. A phase I study of chemically synthesized verotoxin (Shiga-like toxin) Pktrisaccharide receptors attached to chromosorb for preventing hemolytic-uremic syndrome. J Infect Dis 1995; 171(4): 1042-1045
11. Trachtman H, Cnaan A, Christen E, et al. Effect of an oral Shiga toxin-binding agent on diarrhea-associated hemolytic uremic syndrome in children: a randomized controlled trial. Jama 2003; 290(10): 1337-1344.
12. Gianfaldoni C, Censini S, Hilleringmann M, et al. Streptococcus pneumoniae pilus subunits protect mice against lethal challenge. Infect Immun 2007; 75(2): 1059-1062.
13. Hilleringmann M, Pansegrau W, Doyle M, et al. Inhibitors of Helicobacter pylori ATPase Cagalpha block CagA transport and cag virulence. Microbiology 2006; 152(Pt 10): 2919-2930.
14. Liu CI, Liu GY, Song Y, et al. A cholesterol biosynthesis inhibitor blocks Staphylococcus aureus virulence. Science 2008; 319(5868): 1391-1394
15. Srinivas N, Jetter P, Ueberbacher BJ, et al. Peptidomimetic antibiotics target outer-membrane biogenesis in Pseudomonas aeruginosa. Science 2010; 327(5968): 1010-1013.
16. Veenendaal AK, Sundin C, Blocker AJ. Small-molecule type III secretion system inhibitors block assembly of the Shigella type III secreton. J Bacteriol 2009; 191(2): 563-570.
17. Muschiol S, Normark S, Henriques-Normark B, Subtil A. Small molecule inhibitors of the Yersinia type III secretion system impair the development of Chlamydia after entry into host cells. BMC Microbiol 2009; 9: 75.
18. Kauppi AM, Andersson CD, Norberg HA, Sundin C, Linusson A, Elofsson M. Inhibitors of type III secretion in Yersinia: Design, synthesis and multivariate QSAR of 2-arylsulfonylaminobenzanilides. Bioorg Med Chem 2007; 15(22): 6994-7011.
19. Pan NJ, Brady MJ, Leong JM, Goguen JD. Targeting type III secretion in Yersinia pestis. Antimicrob Agents Chemother 2009; 53(2): 385-392.
20. Kauppi AM, Nordfelth R, Uvell H, Wolf-Watz H, Elofsson M. Targeting bacterial virulence: inhibitors of type III secretion in Yersinia. Chem Biol 2003; 10(3): 241-249.
21. Aiello D, Williams JD, Majgier-Baranowska H, et al. Discovery and characterization of inhibitors of Pseudomonas aeruginosa type III secretion. Antimicrob Agents Chemother 2010; 54: 1988-1999.
22. Felise HB, Nguyen HV, Pfuetzner RA, et al. An inhibitor of gramnegative bacterial virulence protein secretion. Cell Host Microbe 2008; 4(4): 325-336.
23. Hudson DL, Layton AN, Field TR, et al. Inhibition of type III secretion in Salmonella enterica serovar Typhimurium by smallmolecule inhibitors. Antimicrob Agents Chemother 2007; 51(7): 2631-2635.
24. Negrea A, Bjur E, Ygberg SE, Elofsson M, Wolf-Watz H, Rhen M. Salicylidene acylhydrazides that affect type III protein secretion in Salmonella enterica serovar typhimurium. Antimicrob Agents Chemother 2007; 51(8): 2867-2876.
25. Tree JJ, Wang D, McInally C, et al. Characterization of the effects of salicylidene acylhydrazide compounds on type III secretion in Escherichia coli O157: H7. Infect Immun 2009; 77(10): 4209-4220.
26. Muschiol S, Bailey L, Gylfe A, et al. A small-molecule inhibitor of type III secretion inhibits different stages of the infectious cycle of Chlamydia trachomatis. Proc Natl Acad Sci USA 2006; 103(39): 14566-14571.
27. Bailey L, Gylfe A, Sundin C, et al. Small molecule inhibitors of type III secretion in Yersinia block the Chlamydia pneumoniae infection cycle. FEBS Lett 2007; 581(4): 587-595.
28. Hueck CJ. Type III protein secretion systems in bacterial pathogens of animals and plants. Microbiol Mol Biol Rev 1998; 62(2): 379-433.
29. Yahr TL, Mende-Mueller LM, Friese MB, Frank DW. Identification of type III secreted products of the Pseudomonas aeruginosa exoenzyme S regulon. J Bacteriol 1997; 179(22): 7165-7168.
30. Alto NM, Shao F, Lazar CS, et al. Identification of a bacterial type III effector family with G protein mimicry functions. Cell 2006; 124(1): 133-1345.
31. deCathelineau AM, Bokoch GM. Inactivation of rho GTPases by statins attenuates anthrax lethal toxin activity. Infect Immun 2009; 77(1): 348-359.
32. Coburn B, Sekirov I, Finlay BB. Type III secretion systems and disease. Clin Microbiol Rev 2007; 20(4): 535-5349.
33. Lilo S, Zheng Y, Bliska JB. Caspase-1 activation in macrophages infected with Yersinia pestis KIM requires the type III secretion system effector YopJ. Infect Immun 2008; 76(9): 3911-3923.
34. Wangdi T, Mijares LA, Kazmierczak BI. In vivo discrimination of type 3 secretion system-positive and -negative Pseudomonas aeruginosa via a caspase-1-dependent pathway. Infect Immun 2010; 78(11): 4744-4753.
35. Srikanth CV, Wall DM, Maldonado-Contreras A, et al. Salmonella pathogenesis and processing of secreted effectors by caspase-3. Science 2010; 330(6002): 390-393.
36. Rosqvist R, Magnusson KE, Wolf-Watz H. Target cell contact triggers expression and polarized transfer of Yersinia YopE cytotoxin into mammalian cells. Embo J 1994; 13(4): 964-972.
37. Anderson DM, Ramamurthi KS, Tam C, Schneewind O. YopD and LcrH regulate expression of Yersinia enterocolitica YopQ by a posttranscriptional mechanism and bind to yopQ RNA. J Bacteriol 2002; 184(5): 1287-1295.
38. Ramamurthi KS, Schneewind O. Type iii protein secretion in yersinia species. Annu Rev Cell Dev Biol 2002; 18: 107-133
39. Cornelis GR. The type III secretion injectisome. Nat Rev Microbiol 2006; 4(11): 811-825.
40. Wang D, Roe AJ, McAteer S, Shipston MJ, Gally DL. Hierarchal type III secretion of translocators and effectors from Escherichia coli O157: H7 requires the carboxy terminus of SepL that binds to Tir. Mol Microbiol 2008; 69(6): 1499-1512.
41. Rosqvist R, Hakansson S, Forsberg A, Wolf-Watz H. Functional conservation of the secretion and translocation machinery for virulence proteins of yersiniae, salmonellae and shigellae. Embo J 1995; 14(17): 4187-4195.
42. Kimbrough TG, Miller SI. Contribution of Salmonella typhimurium type III secretion omponents to needle complex formation. Proc Natl Acad Sci USA 2000; 97(20): 11008-11013.
43. Kimbrough TG, Miller SI. Assembly of the type III secretion needle complex of Salmonella typhimurium. Microbes Infect 2002; 4(1): 75-82.
44. Kubori T, Matsushima Y, Nakamura D, et al. Supramolecular structure of the Salmonella typhimurium type III protein secretion system. Science 1998; 280(5363): 602-605.
45. Marlovits TC, Kubori T, Sukhan A, Thomas DR, Galan JE, Unger VM. Structural insights into the assembly of the type III secretion needle complex. Science 2004; 306(5698): 1040-1042.
46. Blocker A, Jouihri N, Larquet E, et al. Structure and composition of the Shigella flexneri needle complex, a part of its type III secreton. Mol Microbiol 2008; 39(3): 652-663.
47. Spreter T, Yip CK, Sanowar S, et al. A conserved structural motif mediates formation of the periplasmic rings in the type III secretion system. Nat Struct Mol Biol 2009; 16(5): 468-476.
48. Genin S, Boucher CA. A superfamily of proteins involved in different secretion pathways in gram-negative bacteria: modular structure and specificity of the N-terminal domain. Mol Gen Genet 1994; 243(1): 112-118.
49. Marlovits TC, Kubori T, Lara-Tejero M, Thomas D, Unger VM, Galan JE. Assembly of the inner rod determines needle length in the type III secretion injectisome. Nature 2006; 441(7093): 637-640.
50. Yip CK, Kimbrough TG, Felise HB, et al. Structural characterization of the molecular platform for type III secretion system assembly. Nature 2005; 435(7042): 702-707.
51. Schraidt O, Lefebre MD, Brunner MJ, et al. Topology and organization of the Salmonella typhimurium type III secretion needle complex components. PLoS Pathog 2010; 6(4): e1000824.
52. Sanowar S, Singh P, Pfuetzner RA, et al. Interactions of the transmembrane polymeric rings of the Salmonella enterica Serovar Typhimurium Type III secretion system. MBio 2010; 1(3): e00158-e00160. doi: 10.1128/mBio.-10.
53. Moraes TF, Spreter T, Strynadka NC. Piecing together the type III injectisome of bacterial pathogens. Curr Opin Struct Biol 2008; 18(2): 258-266.
54. Lario PI, Pfuetzner RA, Frey EA, et al. Structure and biochemical analysis of a secretin pilot protein. Embo J 2005; 24(6): 1111-1121.
55. Derewenda U, Mateja A, Devedjiev Y, et al. The structure of Yersinia pestis V-antigen, an essential virulence factor and mediator of immunity against plague. Structure 2004; 12(2): 301-306.
56. Deane JE, Cordes FS, Roversi P, et al. Expression, purification, crystallization and reliminary crystallographic analysis of MxiH, a subunit of the Shigella flexneri type III secretion system needle. Acta Crystallogr Sect F Struct Biol Cryst Commun 2006; 62(Pt 3): 302-305.
57. Deane JE, Roversi P, Cordes FS, et al. Molecular model of a type III secretion system needle: Implications for host-cell sensing. Proc Natl Acad Sci USA 2006; 103(33): 12529-12533.
58. Quinaud M, Ple S, Job V, et al. Structure of the heterotrimeric complex that regulates type III secretion needle formation. Proc Natl Acad Sci USA 2007; 104(19): 7803-7808.
59. Crepin VF, Prasannan S, Shaw RK, et al. Structural and functional studies of the enteropathogenic Escherichia coli type III needle complex protein EscJ. Mol Microbiol 2005; 55(6): 1658-1670.
60. Schubot FD, Jackson MW, Penrose KJ, et al. Three-dimensional structure of a macromolecular assembly that regulates type III secretion in Yersinia pestis. J Mol Biol 2005; 346(4): 1147-1161.
61. Zarivach R, Vuckovic M, Deng W, Finlay BB, Strynadka NC. Structural analysis of a prototypical ATPase from the type III secretion system. Nat Struct Mol Biol 2007; 14(2): 131-137.
62. Schubot FD, Cherry S, Austin BP, Tropea JE, Waugh DS. Crystal structure of the protease-resistant core domain of Yersinia pestis virulence factor YopR. Protein Sci 2005; 14(6): 1679-1683.
63. Blaylock B, Berube BJ, Schneewind O. YopR impacts type III needle polymerization in Yersinia species. Mol Microbiol 2010; 75(1): 221-229.
64. Shortridge MD, Powers R. Structural and functional similarity between the bacterial type III secretion system needle protein PrgI and the eukaryotic apoptosis Bcl-2 proteins. PLoS One 2009; 4(10): e7442.
65. Wang Y, Ouellette AN, Egan CW, Rathinavelan T, Im W, De Guzman RN. Differences in the electrostatic surfaces of the type III secretion needle proteins PrgI, BsaL, and MxiH. J Mol Biol 2007; 371(5): 1304-1314.
66. Linington RG, Robertson M, Gauthier A, Finlay BB, van Soest R, Andersen RJ. Caminoside A, an antimicrobial glycolipid isolated from the marine sponge Caminus sphaeroconia. Org Lett 2002; 4(23): 4089-4092.
67. Linington RG, Robertson M, Gauthier A, et al. Caminosides B-D, antimicrobial glycolipids isolated from the marine sponge Caminus sphaeroconia. J Nat Prod 2006; 69(2): 173-7.
68. Sun J, Han X, Yu B. First Total Synthesis of Caminoside A, an Antimicrobial Glycolipid from Sponge. Synlett 2005; (3): 437-440.
69. Gauthier A, Robertson ML, Lowden M, Ibarra JA, Puente JL, Finlay BB. Transcriptional inhibitor of virulence factors in enteropathogenic Escherichia coli. Antimicrob Agents Chemother 2005; 49(10): 4101-4109.
70. Yount JS, Tsou LK, Dossa PD, Kullas AL, van der Velden AW, Hang HC. Visible Fluorescence Detection of Type III Protein Secretion from Bacterial Pathogens. J Am Chem Soc 2010; 132(24): 8244-8245.
71. Nordfelth R, Kauppi AM, Norberg HA, Wolf-Watz H, Elofsson M. Small-molecule inhibitors specifically targeting type III secretion. Infect Immun 2005; 73(5): 3104-3104.
72. O'Shea R, Moser HE. Physicochemical properties of antibacterial compounds: implications for drug discovery. J Med Chem 2008; 51(10): 2871-2878.
73. Kline T, Barry KC, Jackson SR, Felise HB, Nguyen HV, Miller SI. Tethered thiazolidinone dimers as inhibitors of the bacterial type III secretion system. Bioorg Med Chem Lett 2009; 19(5): 1340-1343.
74. Kline T, Felise HB, Barry KC, Jackson SR, Nguyen HV, Miller SI. Substituted 2-Imino-5-arylidenethiazolidin-4-one Inhibitors of Bacterial Type III Secretion. J Med Chem 2008; 51(22): 7065-7074.
75. Pan N, Lee C, Goguen J. High throughput screening for smallmolecule inhibitors of type III secretion in Yersinia pestis. Adv Exp Med Biol 2007; 603: 367-375.
76. Li X. Inhibitors of bacterial type III secretion systems. US patent 0272784 A1, 2005.
77. Li X, Kang F-A, Macielag MJ. Triazine compounds as inhibitors of bacterial type III protein secretion systems. PCT/US2005/ 015808 WO2005/111017, 2005.
78. Li X. Pyridone compounds as inhibitors of bacterial type II protein secretion systems. US 7,987,622 B2, 2006.
79. Iwatsuki M, Uchida R, Yoshijima H, et al. Guadinomines, Type III secretion system inhibitors, produced by Streptomyces sp. K01-0509. II: physico-chemical properties and structure elucidation. J Antibiot (Tokyo) 2008; 61(4): 230-236.
80. Iwatsuki M, Uchida R, Yoshijima H, et al. Guadinomines, Type III secretion system inhibitors, produced by Streptomyces sp. K01-0509. I: taxonomy, fermentation, isolation and biological properties. J Antibiot (Tokyo) 2008; 61(4): 222-229.
81. Abe T, Fukuoka T, Sato Y, Ito K, Sei M. [Antibacterial activity of cefpodoxime against clinical isolates in 2000 and 2001]. Jpn J Antibiot 2002; 55(6): 827-843.
82. Hirose T, Sunazuka T, Tsuchiya S, et al. Total synthesis and determination of the absolute configuration of guadinomines B and C2. Chemistry 2008; 14(27): 8220-8228.
83. Levy SB, Alekshun MN, Podlogar BL, et al. Transcription factor modulating compounds and methods of use thereof. USA Patent US2003229065 A1 20031211, 2003.
84. Levy SB, Alekshun MN, Podlogar BL, et al. Substituted benzimidazole compounds as transcription factor modulating compounds useful as anti-infective. US Patent Application USA 2005124678 A1 20050609, 2005.
85. Alekshyn MN, Amoo V, Kim OK, Verma AK. Benzimidazole derivative transcription factor-modulating compounds for use as antiinfective agents. PkCT Int Appl WO 2006076009 A2 20060720, 2006.
86. Lee VT, Pukatzki S, Sato H, et al. Pseudolipasin A is a specific inhibitor for phospholipase A2 activity of Pseudomonas aeruginosa cytotoxin ExoU. Infect Immun 2007; 75(3): 1089-1098.
87. Lee K, Boovanahalli SK, Nam KY, et al. Synthesis of tripeptides as potent Yersinia protein tyrosine phosphatase inhibitors. Bioorg Med Chem Lett 2005; 15(18): 4037-4042.
88. Kim OK, Garrity-Ryan LK, Bartlett VJ, et al. Nhydroxybenzimidazole inhibitors of the transcription factor LcrF in Yersinia: novel antivirulence agents. J Med Chem 2009; 52(18): 5626-5634.
89. Mouratou B, Schaeffer F, Guilvout I, et al. Remodeling a DNAbinding protein as a specific in vivo inhibitor of bacterial secretin PulD. Proc Natl Acad Sci USA 2007; 104(46): 17983-17988.
90. Bebbington C, Yarranton G. Antibodies for the treatment of bacterial infections: current experience and future prospects. Curr Opin Biotechnol 2008; 19(6): 613-619.
91. Cowan C, Philipovskiy AV, Wulff-Strobel CR, Ye Z, Straley SC. Anti-LcrV antibody inhibits delivery of Yops by Yersinia pestisKIM5 by directly promoting phagocytosis. Infect Immun 2005; 73(9): 6127-6137.
92. Faure K, Fujimoto J, Shimabukuro DW, et al. Effects of monoclonal anti-PcrV antibody on Pseudomonas aeruginosainduced acute lung injury in a rat model. J Immune Based Ther Vaccines 2003; 1(1): 2.
93. Goure J, Broz P, Attree O, Cornelis GR, Attree I. Protective anti-V antibodies inhibit Pseudomonas and Yersinia translocon assembly within host membranes. J Infect Dis 2005; 192(2): 218-225.
94. Philipovskiy AV, Cowan C, Wulff-Strobel CR, et al. Antibody against V antigen prevents Yop-dependent growth of Yersinia pestis. Infect Immun 2005; 73(3): 1532-1542.
95. Frank DW, Vallis A, Wiener-Kronish JP, et al. Generation and characterization of a protective monoclonal antibody to Pseudomonas aeruginosa PcrV. J Infect Dis 2002; 186(1): 64-73.
96. Payne DJ, Gwynn MN, Holmes DJ, Pompliano DL. Drugs for bad bugs: confronting the hallenges of antibacterial discovery. Nat Rev Drug Discov 2007; 6(1): 29-40.
97. Cegelski L, Marshall GR, Eldridge GR, Hultgren SJ. The biology and future prospects of antivirulence therapies. Nat Rev Microbiol 2008; 6(1): 17-27.
98. Pineyro P, Zhou X, Orfe LH, Friel PJ, Lahmers K, Call DR. Development of two animal models to study the function of Vibrio parahaemolyticus type III secretion systems. Infect Immun 2010; 78(11): 4551-4559.
99. Garrity-Ryan LK, Kim OK, Balada-Llasat JM, et al. Small molecule inhibitors of LcrF, a Yersinia pseudotuberculosis transcription factor, attenuate virulence and limit infection in a murine pneumonia model. Infect Immun 2010; 78(11): 4683-4690.
100. Alksne LE, Projan SJ. Bacterial virulence as a target for antimicrobial chemotherapy. Curr Opin Biotechnol 2000; 11(6): 625-666.